New PET scan may predict breast cancer treatment success
NCT ID NCT03321045
First seen Jan 30, 2026 · Last updated May 22, 2026 · Updated 14 times
Summary
This early-phase study tests a new PET scan that uses a radioactive tracer (89Zr-trastuzumab) to see how much HER2 protein is in breast cancer tumors. The goal is to find out if this scan can predict which patients will respond to HER2-targeted therapy. About 10 adults with newly diagnosed HER2-positive breast cancer will receive the tracer and then have a PET/MRI scan. The study aims to improve treatment selection and avoid ineffective therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Kirklin Clinic
RECRUITINGBirmingham, Alabama, 35249, United States
Conditions
Explore the condition pages connected to this study.